Colorectal Cancer Awareness Month
Over 51,000 people living in the United States died of colorectal cancer in 2019, according to federal estimates. Although this type of cancer can be preventable, it is the second leading cause of cancer death in the United States behind only lung cancer.
Colonoscopy screening can prevent colorectal cancer because precancerous polyps found during the procedure can be removed at the same time, before they ever develop into cancers. The procedure can also detect colorectal cancers at an early stage, before they have spread, when successful treatment is more likely. In fact, the five-year survival rate for localized colorectal cancer is 89.9 percent, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.
March is Colorectal Cancer Awareness Month.
In 2019, an estimated 145,600 people in the United States were diagnosed with colorectal cancer.
Colorectal cancer is more common in men than women. It is also more common among African Americans than people of other races. The median age of diagnosis in the United States is 67 years, and 78 percent of newly diagnosed patients are aged 55 and older.
In October 2021, the AACR will hold its fourth colorectal cancer-focused special conference, in Minneapolis.
In 2019, the AACR offered the following awards in the field of colorectal cancer research:
- AACR-MEG Scholar-in-Training Award: Xiang Shu, PhD, Vanderbilt University Medical Center
- AACR Minority Scholar in Cancer Research Award: Doratha A. Byrd, PhD, MPH, Emory University
- AACR Minority and Minority-Serving Institution Faculty Scholars in Cancer Research: Luciana Madeira da Silva, PhD, Assistant Professor, University of South Alabama
- AACR-Get Your Rear in Gear Philadelphia Scholar-in-Training Awards Supported by the Colon Cancer Coalition: Erica K. Barnell, Washington University School of Medicine; Naghma Khan, PhD, University of Wisconsin-Madison; Xiangqian Kong, PhD, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center; Trine B. Mattesen, MS, Aarhus University Hospital (Denmark); Xiaoliang (Wendy) Wang, PhD, Fred Hutchinson Cancer Research Center